HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


A Lesson In Exclusivity? Claritin Falters As Generic Loratadine Sales Double

This article was originally published in The Tan Sheet

Executive Summary

The absence of Hatch/Waxman exclusivity for Schering-Plough's nonprescription Claritin has cost the company millions in potential revenue despite the drug's position as the most successful Rx-to-OTC switch to date

You may also be interested in...

Claritin 12-Hour Takes Aim At Shorter-Duration Allergy Drugs

Schering-Plough extends the Claritin line into the 12-hour allergy relief niche to go after first-generation antihistamines with shorter durations

Perrigo Predicts Cough/Cold Sales Drop Due To Pseudoephedrine BTC Move

Perrigo's cough/cold sales will likely be hurt in fiscal 2006 as retailers restrict pseudoephedrine products to behind-the-counter sale, according to the firm

Schering Prepares For “Turnaround”; Claritin Falls Flat In First Quarter

Schering-Plough's Claritin experienced another relatively flat quarter despite an increase in promotional spending

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts